Browse > Article

Pharmacokinetic Interaction between Verapamil and Tamoxifen in Rats  

Seol, Hyo-Chan (Korean Food and Drug Administration)
Choi, Jun-Shik (College of Pharmacy, Chosun University)
Publication Information
YAKHAK HOEJI / v.49, no.5, 2005 , pp. 380-385 More about this Journal
Abstract
The aim of this study is to investigate the effects of verapamil on the pharmacokinetics of tamoxifen following oral administration of tamoxifen with verapamil to rats. Tamoxifen (10 mg/kg) was administered orally in the presence or absence of verapamil (1, 3 or 6 mg/kg). Compared to the control group (given tamoxifen alone), the presence of verapamil significantly (p<0.05 by 1 mg/kg, p<0.01 by 3 and 6 mg/kg) increased the areas under the plasma concentration-time curve (AUC) and the peak concentrations ($C_{max}$) of tamoxifen. Consequently, the relative bioavailability ($RB\%$) of tamoxifen with verapamil was 1.6-2.1 fold higher than that of the control. But the time to reach peak concentration ($T_{max}$) and the terminal half-life ($t_{1/2}$) of tamoxifen were not altered significantly in the presence of verapamil. The increased AUC and $C_{max}$ of tamox­ifen in the presence of verapamil might be associated with the inhibition by verapamil of the P-glycoprotein and the first­pass metabolizing enzyme CYP3A4 in small intestinal mucosa. The drug interaction should be taken into consideration when tamoxifen is used to the patient with verapamil in the clinical setting.
Keywords
tamoxifen; verapamil; pharmacokinetics; coadministration;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Jaiyesirni, I. A. Buzdar, A. U. Decker, D. A. and Hortobagyi, G. N. : Use of tamoxifen for breast cancer: twenty-eight years later. J Clin. Oncol. 13, 513 (1995)   DOI
2 Robinson, E. Kimmick, G. G. and Muss, H. B. : Tamoxifen in postmenopausal women a safety perspective. Drugs Aging. 8, 329 (1996)   DOI   ScienceOn
3 Lim, C. K. Yuan, Z. X. Lamb, J. H. White, I. N. H. De Matteis, F. and Smith, L. L. : A comparative study of tamoxifen metabolism in female rat, mouse and human liver microsomes. Carcinogenesis. 15, 589 (1994)   DOI   ScienceOn
4 Cordon-Cardo, C., O'Brien, J. P., Casals, D., Rittman-Grauer, L., Biedler, J. L., Melamed, M. R. and Bertino, J. R. : Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. U.S.A. 86, 695 (1989)
5 Reynolds, J. E. F. : Martindale - The Extra Pharmacopeia, Pharmaceutical Press. London (1993)
6 Burton, P. S., Conradi, R. A., Hilgers, A. R. and Ho, N. F. : Evidence for a polarized efflux for peptides in the apical membrane of Caco-2 cells. Biochem. Biophys. Res. Commun. 190, 760 (1993)   DOI   ScienceOn
7 Choi, J. S., Jo, B. W. and Kim, Y. C. : Enhanced bioavailability after oral administration of paclitaxel or prodrug to rats pretreated with quercetin. Eur. J Pharm. Biopharm. 57, 313 (2004)   DOI   ScienceOn
8 Candussio, L., Decorti, G., Crivellato, E., Granzotto, M., Rosati, A., Giraldi, T. and Bartoli, F. : Toxicologic and pharmacokinetic study of low doses of verapamil combined with doxorubicin. Life Sci. 71, 3109 (2002)   DOI   ScienceOn
9 Verschraagen, M., Koks, C. H., Schellens, J. H. and Beijnen, J. H. : P-glycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil. Pharmacol. Res. 40, 301 (1999)   DOI   ScienceOn
10 Powles, T. J. : The case for clinical trials of tamoxifen for prevention of breast cancer. Lancet. 340, 1145 (1992)   DOI   ScienceOn
11 Wacher, V. H., Silverman, J. A., Zhang, Y. and Benet, L. Z. : Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of pep tides and peptidomimetics. J. Pharm. Sci. 87, 1322 (1998)   DOI
12 Zhou, S., Yung Chan, S., Cher Goh, B., Chan, E., Duan, W., Huang, M. and McLeod, H. L. : Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin. Pharmacokinet. 44, 279 (2005)   DOI   ScienceOn
13 Rocci, M. L. and Jusko, W. J. : LAGRAN program for area and moments in pharmacokinetic analysis. Computer Programs in Biomedicine 16, 203 (1983)   DOI   ScienceOn
14 Choi, J. S. and Li, X. : The effect of verapamil on the pharmacokinetics of paclitaxel in rats. Eur. J. Pharm. Sci. 24, 95 (2005)   DOI   ScienceOn
15 Dehal, S. S. and Kupfer, D. : Cytochrome P-450 3A and 2D6 catalyze ortho hydroxylation of 4-hydroxytamoxifen and 3-hydroxytamoxifen (droloxifene) yielding tamoxifen catechol: involvement of catechols in covalent binding to hepatic proteins. Drug. Metab. Dispos. 27, 681 (1999)
16 DeGregorio, M. W., Coronado, E. and Osborne, C. K. : Tumor and serum tamoxifen concentrations in the athymic nude mice. Cancer Chemother. Pharmacol. 23, 68 (1989)   DOI
17 Robinson, S. P., Langan-Fahey, S. M. and Jordan, V. C. : Implications of tamoxifen metabolism in the athymic mouse for the study of antitumor effects upon human breast cancer xenografts. Eur. J. Cancer Clin. Oncol. 25, 1769 (1989)   DOI   ScienceOn
18 Choi J. S. and Lee, C. K. : Pharmacokinetic interaction between nifedipine and paclitaxel in rats. J. Pharm. Soc. Korea 48, 61 (2004)
19 Fried, K. M. and Wainer, I. W. : Direct determination of tamoxifen and its four major metabolites in plasma using coupled column high-performance liquid chromatography. J. Chromatogr. B. Biomed. Appl. 655, 261 (1994)   DOI   ScienceOn
20 Gan, L.-S. L., Moseley, M. A., Khosla, B., Augustijns, P. E, Bradshaw, T. P., Hendren, R. W. and Thakker, D. R. : CYP3A-Like cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells: interaction between the two biochemical barriers to intestinal transport. Drug Metab. Dispos. 24, 344 (1996)
21 Magnarin, M., Morelli, M., Rosati, A., Bartoli, F., Candussio, L., Giraldi, T. and Decorti. G. : Induction of proteins involved in multidrug resistance (P-glycoprotein, MRP1, MRP2, LRP) and of CYP 3A4 by rifampicin in LLC-PKI cells. Eur. J. Pharmacol. 483, 19 (2004)   DOI   ScienceOn
22 Rao, U. S., Fine R. L. and Scarborough, G. A. : Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem. Pharmacol. 48, 287 (1994)   DOI   ScienceOn
23 Lewis, G. R., Morley, K. D., Lewis, B. M. and Bones, P. J. : The treatment of hypertension with veraparnil, N. Z. Med. J. 87, 351 (1978)
24 Scambia, G., Ranelletti, F.O., Panici, P. B., De Vincenzo, R., Bonanno, G., Frrandina, G., Paiantelli, M., Bussa, S., Rumi, C. and Cianfriglia, M. et al. : Quercetin potentiates the effect of adriamycin in a multidurg-resistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target. Cancer Chemother. Pharmacol. 36, 459 (1994)   DOI   ScienceOn
25 Kerr, D. J., Graham, J., Cummings, J., Morrison, J. G., Thompson, G. G., Brodie, M. J. and Kaye, S. B. : The effect of verapamil on the pharmacokinetics of adriamycin. Cancer Chemother. Pharmacol. 18, 239 (1986)
26 Swenberg, J. A. : Clinical relevance of laboratory and animal data on tamoxifen. Oncology (Huntingt) 11, 39 (1997)
27 Simon, I., Berthou, F., Riche, C., Beaune, P. and Ratanasavanh, D. : Both cytochromes P4501Al and 3A4 are involved in the N-demethylation of tamoxifen, In: Proceedings of the Fifth European ISSX Meeting Tours, France, Abstract No. 44 (1993)
28 Mani, C., Gelboin, H. V., Park, S. S., Pearce, R., Parkinson, A. and Kupfer, D. : Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. I. Cytochrome P450-catalysed N-demethylation and 4-hydroxylation. Drug Metab. Dispos. 21, 645 (1993)
29 Jordan, V. C., Collins, M. M., Rowsby, L. and Prestwich, G. : A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J. Endocrinol. 75, 305 (1977)   DOI   ScienceOn
30 Leveque, D. and Jehl, F. : P-glycoprotein and pharmacokinetics. Anticancer Res. 15, 331 (1995)
31 Hotta, T., Tanimura, H., Yamaue, H., Iwahashi, M., Tani, M., Tsunoda, T., Tarnai, M., Noguchi, K., Mizobata, S., Arii, K. and Terasawa, H. : Tamoxifen circumvents the multidrug resistance in fresh human gastrointestinal cancer cells. J. Surg. Res. 66, 31 (1996)   DOI   ScienceOn
32 Ito, K., Kusuhara, H. and Sugiyama, Y. : Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption theoretical approach. Pharm. Res. 16, 225 (1999)   DOI   ScienceOn
33 Buckley, M. T. and Goa, K L. : Tamoxifen: a reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use. Clin. Pharmacokin. 37, 451 (1989)
34 Stone, R. : NIH fends off critics of tamoxifen study. Science 258, 734 (1992)   DOI   PUBMED
35 Krikler, D. M. and Spurrell, R. A. : Verapamil in the treatment of paroxysmal supraventricular tachycardia. Postgrad. Med. J. 50, 447 (1974)   DOI   ScienceOn
36 Crewe, H. K., Ellis, S. W., Lennard, M. S. and Tucker, G. T. : Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem. Pharmacol. 53, 171 (1997)   DOI   ScienceOn
37 Gant, T. W., O'Connor, C. K., Corbitt, R., Thorgeirsson, U. and Thorgeirsson, S. S. : In vivo induction of liver P-glycoprotein expression by xenobiotics in monkeys. Toxicol. Appl. Pharmacol. 133, 269 (1995)   DOI   ScienceOn
38 Gottesman, M. M. and Pastan, I. : Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62, 385 (1993)   DOI   ScienceOn
39 Choi, J. S. and Kim, H. J. : Pharmacokinetic interaction between diltiazem and paclitaxel in rats. J. Kor. Pharm. Soc. 33, 299 (2003)
40 Shao, Y. M., Ayesh, S. and Stein, W. D. : Mutually co-operative interactions between modulators of P-glycoprotein. Biochim. Biophys. Acta. 1360, 30 (1997)   DOI   ScienceOn
41 Watkins, P. B. : The barrier function of CYP3A4 and Pglycoprotein in the small bowel. Adv. Drug Deliv. Rev. 27, 161 (1996)   DOI   ScienceOn
42 Jacolot, F., Simon, I., Dreano, I., Beaune, P., Riche, C. and Berthou, F. : Identification of the cytochrome P450 IIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes. Biochem. Pharmacol. 41, 1911 (1991)   DOI   ScienceOn
43 Mani, C., Gelboin, H. V., Park, S. S., Pearce, R., Parkinson, A. and Kupfer, D. : Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. I. Cytochrome P-450-catalyzed N-demethylation and 4-hydroxylation. Drug Metab. Dispos. 21, 645 (1993)
44 Berthou, F., Dreano, Y., Belloc, C., Kangas, L., Gautier, J. C. and Beaune, P. : Involvement of cytochrome P450 3A enzyme family in the major metabolic pathways of toremifene in human liver microsomes. Biochem. Pharmacol. 47, 1883 (1994)   DOI   ScienceOn
45 Daniel, P. C., Gaskell, J., Bishop, H., Campbell, C. and Nicholson, R. : Determination of tamoxifen and biologically active metabolites in human breast tumour and plasma. Eur. J. Cancer Clin. Oncol. 17, 1183 (1981)   DOI   ScienceOn
46 Sugawara, I., Kataoka, I., Morishita, Y., Hamada, H., Tsuruo, T., Itoyama, S. and Mori, S. : Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16. Cancer Res. 48, 1926 (1988)
47 Gould, B. A., Mann, S., Kieso, H., Subramanian, V. B. and Raftery, E. B. : The 24-hour ambulatory blood pressure profile with verapamil. Circulation 65, 22 (1982)   DOI   ScienceOn
48 Thiebaut, F., Tsuruo, T., Hamada, H., Cottesman, M. M., Pastan, I. and Willingham, M. C. : Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. U.S.A. 84, 7735 (1987)
49 Mani, C., Pearce, R., Parkinson, A. and Kupfer, D. : Involvement of cytochrome P4503A in catalysis of tamoxifen activation and covalent binding to rat and human liver microsomes. Carcinogenesis. 15, 2715 (1994)   DOI   ScienceOn
50 Zhang, H., Wong, C. W., Coville P. F. and Wanwimolruk, S. : Effect of the grapefruit flavonoid naringin on pharmacokinetics of quinine in rats. Drug Metabol. Drug Interact. 17, 351 (2000)
51 Hunter, J., Jepson, M. A., Tsuruo, T., Simmons, N. L. and Hirst, B. H. : Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. Kinetics of vinblastine secretion and interaction with modulators. J. BioI. Chem. 268, 14991 (1993)